PVR and non-small cell lung carcinoma: Similarly, worse clinical responses to anti-PD-1 therapy were found in NSCLC cases harboring CD155 positivity (ORR 25.6% vs. 54.8%; p < 0.01), even as first-line or later-line treatment [7].